Full Press Release Details
Update on extraintestinal pathogenic E. coli vaccine phase 3 clinical study
Paris, February 13, 2025. A scheduled review of the E.mbrace phase 3 study (clinical trial identifier: NCT04899336) conducted by an
independent data monitoring committee (IDMC) determined that Sanofi and Johnson & Johnson s vaccine candidate for extraintestinal pathogenic E. coli was not sufficiently effective at preventing invasive E. coli disease
(IED) compared to placebo. No safety signals related to the vaccine candidate were identified and, throughout the study, investigators ensured that participants who developed IED received prompt treatment and care. As a result of the IDMC s
determination, the E.mbrace study is being discontinued.
Jean-Fran ois Toussaint
Global Head of Research and Development Vaccines, Sanofi
E. coli sepsis is a devastating disease and there are no preventative measures available to date. Driven by our ambition to transform
the practice of medicine, we entered this ambitious although challenging field. We are disappointed to see that the vaccine was not associated with sufficient efficacy to support the trial continuation, and we will work tirelessly to understand the
factors behind the IDMC s finding and to share further analysis once available. We are grateful to the participants, families and healthcare professionals involved in this development program. While disappointed by this outcome, we remain
steadfast in our commitment to drive innovation in R&D by developing first and best-in-class vaccines in areas of high unmet need.
In October 2023, Sanofi entered into an agreement with Janssen Pharmaceuticals, Inc. (Janssen), a Johnson & Johnson company to develop and commercialize the
vaccine candidate. Under the terms of the agreement, both parties agreed to co-fund current and future research and development costs. Sanofi paid $250 million in upfront and development milestones to be
followed by commercial milestones.
The E.mbrace study is a randomized, double-blind, placebo-controlled, multicenter, interventional phase 3 study evaluating the
efficacy, safety, and immunogenicity of a single dose of the vaccine candidate compared to a placebo in the prevention of IED, which includes sepsis and bacteremia (blood infections).
The study was initiated in June 2021 enrolling adults aged 60 years or older in stable health with a history of urinary tract infection in the past two years. The study
was conducted at over 250 sites across five continents. Janssen Research & Development, LLC, is the trial sponsor and responsible party and will continue appropriate safety follow up for the currently enrolled participants.
Financial considerations
As a result of the discontinuation, Sanofi has recorded an impairment charge before tax of $250 million in the Q4 2024 IFRS results. This adjustment impacts
negatively the full-year IFRS EPS reported in the Q4 2024 results press release on January 30, 2025, by 0.15 from 4.59 previously to 4.44 now. This adjustment will be included in Sanofi s Form 20-F for 2024 to be filed with the US Securities and Exchange Commission. However,
there is no impact to the business net income / business EPS remaining unchanged respectively at 8,912 million / 7.12 (non-IFRS). There is no change to the financial guidance for 2025.
We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people s lives. Our team, across
the world, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while
putting sustainability and social responsibility at the center of our ambitions.
Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY
Guendoul | + 33 6 25 09 14 25 | sandrine.guendoul@sanofi.com
Evan Berland | +1 215 432 0234 |
33 6 77 21 27 55 | nicolas.obrist@sanofi.com
L o Le Bourhis | + 33 6 75 06 43 81 | leo.lebourhis@sanofi.com
Victor Rouault | + 33 6 70 93 71 40 |
| + 1 516 521 2929 | timothy.gilbert@sanofi.com
Larsen |+ 44 7545 513 693 | thomas.larsen@sanofi.com
Aliz Kaisserian | + 33 6 47 04 12 11 | alize.kaisserian@sanofi.com
Felix Lauscher | + 1 908 612 7239 |
1 781 249 1766 | keita.browne@sanofi.com
Nathalie Pham | + 33 7 85 93 30 17 | nathalie.pham@sanofi.com
Tarik Elgoutni | + 1 617 710 3587 |
Ch telet | + 33 6 80 80 89 90 | thibaud.chatelet@sanofi.com
Sanofi forward-looking statements
This press release contains forward-looking
statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions,
statements regarding plans, objectives, intentions, and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements
are generally identified by the words expects , anticipates , believes , intends , estimates , plans and similar expressions. Although Sanofi s management believes that the
expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally
beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among
other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug,
device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that
product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi s ability to benefit from external growth opportunities, to complete related transactions and/or
obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic and market
conditions, cost containment initiatives and subsequent changes thereto, and the impact that pandemics or other global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of
them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed
under Risk Factors and Cautionary Statement Regarding Forward-Looking Statements in Sanofi s annual report on Form 20-F for the year ended December 31, 2023. Other than as
required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.
All trademarks mentioned in
this press release are the property of the Sanofi group.